Repositorio
Institucional

Qiu, Ji

Song, Lusheng

Song, Minkyo

Rabkin, Charles S.

Chung, Yunro

Williams, Stacy

Torres, Javier

Corvalan, Alejandro H.

Gonzalez, Robinson

Bellolio, Enrique

Shome, Mahasish

LaBaer, Joshua

Camargo, M. Constanza

Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia

SPRINGER JAPAN KK

JOURNAL OF GASTROENTEROLOGY

en

Background Chronic Helicobacter pylori infection may induce gastric intestinal metaplasia (IM). We compared anti-H. pylori antibody profiles between IM cases and non-atrophic gastritis (NAG) controls. Methods We evaluated humoral responses to 1528 H. pylori proteins among a discovery set of 50 IM and 50 NAG using H. pylori protein arrays. Antibodies with >= 20% sensitivity at 90% specificity for either group were selected and further validated in an independent set of 100 IM and 100 NAG using odds ratios (OR). A validated multi-signature was evaluated using the area under the receiver operating characteristics curve (AUC) and net reclassification improvement (NRI). Results Sixty-two immunoglobulin (Ig) G and 11 IgA antibodies were detected in > 10%. Among them, 22 IgG and 6 IgA antibodies were different between IM and NAG in the discovery set. Validated antibodies included 11 IgG (anti-HP1177/Omp27/HopQ [OR = 8.1, p < 0.001], anti-HP0547/CagA [4.6, p < 0.001], anti-HP0596/Tip alpha [4.0, p = 0.002], anti-HP0103/TlpB [3.8, p = 0.001], anti-HP1125/PalA/Omp18 [3.1, p = 0.001], anti-HP0153/RecA [0.48, p = 0.03], anti-HP0385 [0.41, p = 0.006], anti-HP0243/TlpB [0.39, p = 0.016], anti-HP0371/FabE [0.37, p = 0.017], anti-HP0900/HypB/AccB [0.35, p = 0.048], and anti-HP0709 [0.30, p = 0.003]), and 2 IgA (anti-HP1125/PalA/Omp18 [2.7, p = 0.03] and anti-HP0596/Tip alpha [2.5, p = 0.027]). A model including all 11 IgG antibodies (AUC = 0.81) had better discriminated IM and NAG compared with an anti-CagA only (AUC = 0.77) model (NRI = 0.44, p = 0.001). Conclusions Our study represents the most comprehensive assessment of anti-H. pylori antibody profiles in IM. The target antigens for these novel antibodies may act together with CagA in the progression to IM. Along with other biomarkers, specific H. pylori antibodies may identify IM patients, who would benefit from surveillance.

2023

artículo original

10.1007/s00535-022-01933-0

PDF

Intestinal metaplasia

H

pylori

NAPPA

Serology

Premalignant lesions

Gastroenterología y Hepatología

Microbiología

Metaplasia intestinal

H

pylori

NAPA

Serología

Lesiones premalignas

112.0

124

artículo original

versión publicada

acceso abierto

acceso abierto

WOS:000874428700002

0944-1174

verde# hibrido

Gastroenterología y Hepatología

R01 CA199948

PUC

ANID CONICYT FONDAP 1513001

ANID FONDECYT 1191928